中性粒细胞增多作为接受放化疗的新诊断高级别胶质瘤患者总生存期的生物标志物
本回顾性队列纳入2005年1月至2010年12月在本机构接受替莫唑胺(75 mg/m2每日)同步放疗的连续高级别胶质瘤患者164例,其中胶质母细胞瘤151例(92%)、WHO III级13例(8%)。治疗前中性粒细胞增多(中性粒细胞计数超过7 G/L)者82例(50%),2年实际总生存率为45%。多因素分析显示中性粒细胞增多(p=0.013)、年龄≥65岁(p=0.001)和手术切除<90%(p=0.010)独立降低总生存期,而类固醇消耗未达统计学显著(p=0.088)。
要点
- 治疗前中性粒细胞增多(>7 G/L)见于50%的高级别胶质瘤患者,与更差的总生存期相关(多因素p=0.013)。
- 年龄≥65岁和手术切除<90%同样独立降低总生存期(p=0.001和p=0.010)。
- 泼尼松龙≥60 mg/日增加治疗前中性粒细胞计数(p=0.005),但多因素分析中与总生存期无显著关联(p=0.088)。
核心结论
- 在接受同步替莫唑胺和放疗的高级别胶质瘤中,治疗前中性粒细胞增多可能是总生存期的显著预后因素。
- 结合现有标志物,这一独立且经济有效的生物标志物可能有助于识别预后更差的患者。
研究设计与样本
- 回顾性队列研究,纳入2005年1月至2010年12月在本机构接受同步替莫唑胺(75 mg/m2每日)和放疗的连续高级别胶质瘤患者164例。
- 治疗前中性粒细胞增多定义为中性粒细胞计数超过7 G/L。
主要发现
- 共164例患者,多数(75%)实现初始手术,55例(34%)切除>90%;151例(92%)为胶质母细胞瘤,13例(8%)为WHO III级胶质瘤。
- 82例(50%)存在治疗前中性粒细胞增多;中性粒细胞增多与同步或辅助替莫唑胺中断无关(p>0.3)。
- 2年实际总生存率为45%。
- 泼尼松龙每日60 mg或以上增加治疗前中性粒细胞计数(p=0.005)。
- 单因素分析中,中性粒细胞增多与更差的总生存期相关(p=0.019),年龄≥65岁(p=0.009)、手术切除<90%(p=0.003)和泼尼松龙消耗≥60 mg/日(p=0.016)亦与更差的总生存期相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the prognostic value of neutrophil disorders in a retrospective cohort of high-grade glioma patients receiving definitive concurrent temozolomide and radiation. MATERIALS AND METHODS: Clinical records of consecutive patients treated in our Institution between January 2005 and December 2010 with concurrent temozolomide (75 mg/m2 daily) and radiation were collected. The prognostic value of pretreatment neutrophilia on survival, defined as a neutrophil count exceeding 7 G/L, was examined. RESULTS: We identified 164 patients, all treated with concurrent temozolomide-based chemoradiotherapy. Initial surgery was achieved in most (75%), with resection > 90% in 55 patients (34%). Total 151 patients (92%) had glioblastoma, and 13 patients (8%) had WHO grade III glioma. Eighty-two patients (50%) displayed pretreatment neutrophilia. Neutrophilia was not associated with concurrent or adjuvant temodal discontinuation (p > 0.3). The 2-year actuarial overall survival was 45%. Steroid consumption, i.e. 60 mg or more of daily prednisolone, increased pretreatment neutrophil count (p = 0.005). In univariate analysis, neutrophilia was associated with worse overall survival (p = 0.019), as well as age ≥ 65 years (p = 0.009), surgical resection < 90% (p = 0.003) and prednisolone consumption ≥ 60 mg/day (p = 0.016). In multivariate analysis, neutrophilia (p = 0.013), age ≥ 65 (p = 0.001), and surgical tumor resection < 90% (p = 0.010) independently decreased overall survival, while, steroid consumption was not (p = 0.088). CONCLUSION: In high-grade gliomas treated with concurrent temozolomide and radiation, pretreatment neutrophilia may be a significant prognosis factor for overall survival. In addition with previously available markers, this independent cost-effective biomarker could help identifying patients with worsened prognosis.
引用
- Schernberg A, Nivet A, Dhermain F, et al. Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. Clin Transl Radiat Oncol. 2018. PMID: 29928705. doi:10.1016/j.ctro.2018.04.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。